UNSPSC 51281643: Capreomycin sulfate

This classification denotes an antitubercular agent and aminoglycoside antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9H8D3J7V21. European Medicines Agency schedules Capreomycin sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01029MIG. Capreomycin sulfate generally arises in the molecular formula C25H46N14O12S. The term 'capreomycin sulfate' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule capreomycin sulfate under HS 29419000 and SITC 54139. Capreomycin sulfate bears US NLM identifiers UMLS ID C0006920 and NCI Concept Code C73797. SMILES: As of Q4 2014, CAPREOMYCIN SULFATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51281643 Capreomycin sulfate, a Commodity code, nominally identifies a specific tuberculosis antibiotic; however, recent state and local opportunities posted under this code do not reflect procurement of capreomycin or related anti-tuberculosis agents. Instead, the opportunities cluster around broader medical and pharmaceutical supply categories — naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and medical first-aid supplies for emergency response — suggesting either misclassification or drift in how jurisdictions tag pharmaceutical procurements. The issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), municipal fire and rescue divisions (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local members across multiple states including Oregon). No single buyer appears more than once in the recent record, and the work being solicited reflects routine replenishment of operational medical inventories rather than specialized anti-tuberculosis therapeutics.

Recent activity concentrates in Florida, Texas, and Minnesota, with geographic reach extending to Oregon through the MMCAP cooperative. Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) for naloxone and drug deactivation systems with annual quantities of 1,900 units and 800 units respectively, delivered quarterly; the City of Tampa's ITB 26P00145 (due March 13, 2026) for 169 line items of medical and first-aid supplies for the Tampa Fire Department Rescue Division with an estimated contract value of $700,000 and a sheltered-market set-aside for certified Small Local Business Enterprises; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (due March 26, 2026) establishing contracts for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers effective July 1, 2026. The code shows limited recent activity directly aligned with its nominal scope, and opportunities actually being purchased appear better matched to broader medical supply codes.